Intellia Therapeutics, Inc. (NTLA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Mon, May 11, 2026before open 41 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 - Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM - Existing cash resources expected to fund operations at least into 2028 and well beyond lonvo-z’s anticipated commercial launc" exhibit
Q3 FY2026 "The company’s existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027." exhibit
Q3 FY2026 "(previously referred to as NTLA-2001) for transthyretin (“ATTR”) amyloidosis, including its expectations regarding the review and potential approval by the U.S. Food and Drug Administration its biologics license application (“BLA”) for lonvo-z, its expectations regarding the planned U.S. launch of lonvo-z in the first quarter of 2027, including its ability to complete lonvo-z commercial readiness efforts in advance of the Prescription Drug User Fee Act date of March 10, 2027, and its belief that lonvo-z could transform the HAE treatment paradigm while also delivering significant value to patie" exhibit
Q2 FY2026 "Exhibit 99.1 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine - Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027 - Enrollment successfully reinitiated in nex-z Phase 3 clinical trials; MAGNITUDE-2 enrollment in ATTRv-PN expected to be completed in second half of 2026 - New genomic insights enhance understanding of nex-z’s profile and potential to deliver clinically meani" exhibit
Q2 FY2026 "Intellia expects the U.S. Food and Drug Administration (FDA) to accept its submission of a biologics license application (BLA) for lonvo-z in the second half of 2026." exhibit
Q2 FY2026 "Intellia remains on track to complete patient enrollment in MAGNITUDE-2 in the second half of 2026." exhibit
Q2 FY2026 "The company’s existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. commercial launch for HAE in the first half of 2027." exhibit
Q2 FY2026 "half of 2026 and the subsequent review and approval of that BLA, its expectations regarding a planned U.S. launch of lonvo-z in the first half of 2027, and its plans to complete patient enrollment in MAGNITUDE-2 of nex-z for hereditary ATTR amyloidosis with polyneuropathy in the second half of 2026; the potential of lonvo-z to inactivate the KLKB1 gene to permanently lower kallikrein and bradykinin levels, to eliminate HAE attacks via a highly differentiated one-time treatment that is administered in an outpatient setting, and to transform the treatment paradigm for patients with this burdenso" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NTLA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NTLA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

NTLA earnings date badge

HTML

<a href="https://veritasdata.dev/company/NTLA/"><img src="https://veritasdata.dev/embed/NTLA.svg" alt="NTLA earnings date" width="240" height="56"></a>

Markdown

[![NTLA earnings date](https://veritasdata.dev/embed/NTLA.svg)](https://veritasdata.dev/company/NTLA/)

Script

<script async src="https://veritasdata.dev/embed/NTLA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NTLA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.